Clinical Trials
Braintumor Website

There are 28 trials:
Facility: Northwestern University
NCT Trial Name# of Centers

NCT01814813

  Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
286

NCT02152982

  Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
273

NCT01648348

  Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
242

NCT02360215

  Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases
187

NCT02573324

  A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
185

NCT02179086

  Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
144

NCT02796261

  Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
77

NCT02511405

  A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
53

NCT03180268

  Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
44

NCT01399372

  Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
34

NCT02997423

  Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)
19

NCT02536339

  Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
19

NCT02048059

  ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
17

NCT02078648

  Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
16

NCT01432171

  Lacosamide for Seizure Prophylaxis in High-Grade Gliomas
13

NCT02798406

  Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
13

NCT01967810

  ANG1005 in Patients With Recurrent High-Grade Glioma
11

NCT02357498

  Transsphenoidal Extent of Resection Study
10

NCT00859222

  LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
5

NCT01478321

  Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
5

NCT01898130

  Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
3

NCT02774681

  Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis
3

NCT03071874

  Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas
3

NCT03020017

  NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery
1

NCT02794883

  Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
1

NCT02847559

  Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
1

NCT02530502

  Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma
1

NCT01125046

  Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
1



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites